Milestone is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone’s lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.
Investment year: 2012
Industry sector: Drugs
Milestone Pharmaceuticals Closes $55 Million Series C Financing
BDC Venture Capital Partner